Professor Mark Bradley is Professor of High-Throughput Chemical Biology at the University of Edinburgh. He is the winner of numerous awards including the 2006/7 Novartis lectureship, was recently elected to the Royal Society of Edinburgh, and his group has published over 180 research articles. Formerly, he was the Director of the Combinatorial Centre of Excellence in Southampton. His interests range from the synthesis and screening of compound libraries, the development of novel supports for solid phase chemistry (for both traditional resin based chemistry and for the immobilisation of reagents, scavengers and catalysts) and the application of combinatorial methodologies to the life sciences. These include the development of new protease screening methodologies to multiple presentation arrays and dendrimer library chemistry.

Dr. Peter Edwards brings some thirty years’ experience of drug discovery in the pharmaceutical industry, particularly in anti-infectives and CNS research. He was a Medicinal Chemist at SB Pharmaceuticals, where he led a team researching antibacterial agents with novel mechanisms of action and was part of a team that developed potent inhibitors of bacterial beta lactamase, thus improving the effectiveness of established antibiotics. He pioneered the use of computer technologies for medicinal chemists and worked in a multi¬disciplinary team to streamline the high throughput screening process. Peter is the author of a number of papers and patents.

Dr Tony Ottridge has more than thirty years experience as a working organic chemist, following a PhD at Cambridge in 1976, and a first degree at York in 1973. He spent ten years as a UK government scientist researching into insect chemistry before joining Wyeth and developing expertise in scale-up and process development. Subsequently he became Project Leader at Evotec OAI, applying synthesis knowledge in a highly commercial environment.
He then became Development Team Leader at KuDOS Pharmaceuticals where he was responsible for all chemical aspects of drug development. Tony is equally at home as a project leader or bench chemist, and has an excellent knowledge of scale-up issues and methodology.